Boehringer Ingelheim

Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Fierce Biotech
Boehringer Ingelheim
cystic fibrosis
Oxford BioMedica
gene therapy
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
CP Wire
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
CP Wire
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
Flag link:
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
Flag link:
According to new market survey, pharma industry continues to invest heavily on basic research
According to new market survey, pharma industry continues to invest heavily on basic research
GoinPharma
R&D
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
CP Wire
Boehringer Ingelheim
animal health
Europe
Flag link:
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim BioXcellence adds fill-finish line to China plant
Boehringer Ingelheim BioXcellence adds fill-finish line to China plant
Fierce Pharma
Boehringer Ingelheim
China
drug manufacturing
biologics
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
Flag link:
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires
Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires
Endpoints
Boehringer Ingelheim
R&D
Germany
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
CP Wire
Boehringer Ingelheim
Pradaxa
Praxbind
Flag link:
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
Boehringer Ingelheim
Pradaxa
Praxbind
Flag link:
Pharma's social media strategies are growing up—and working better, too, report finds
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Flag link:
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
exercise
diabetes
Flag link:
Boehringer ends Alzheimer's research for PDE9 blocker
Boehringer ends Alzheimer's research for PDE9 blocker
Biopharma Dive
Boehringer Ingelheim
Alzheimer's disease
PDE9 blockers
BI 409306
Flag link:

Pages